解聚复肾宁治疗早期2型糖尿病肾病

焦颖华; 邢磊; 田发明; 崔立华; 王志文; 孙尧; 李向男

doi:10.11653/syfj2013230317

您当前的位置：

首页 >

文章列表页 >

解聚复肾宁治疗早期2型糖尿病肾病

更新时间：2024-01-04

- 解聚复肾宁治疗早期2型糖尿病肾病
- Clinical Study of Jieju Fushenning in Treatment of Early Type Ⅱ Diabetic Nephropathy
- 中国实验方剂学杂志 2013年19卷第23期页码：317-320
- 作者机构：
- 作者简介：
- 基金信息：
  
  河北省科技计划项目(112761138)
- DOI：10.11653/syfj2013230317
  中图分类号：
- 纸质出版日期：2013
- 稿件说明：
移动端阅览
焦颖华, 邢磊, 田发明, 等. 解聚复肾宁治疗早期2型糖尿病肾病[J]. 中国实验方剂学杂志, 2013,19(23):317-320.

JIAO Ying-hua, XING Lei, TIAN Fa-ming, et al. Clinical Study of Jieju Fushenning in Treatment of Early Type Ⅱ Diabetic Nephropathy[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(23): 317-320.
焦颖华, 邢磊, 田发明, 等. 解聚复肾宁治疗早期2型糖尿病肾病[J]. 中国实验方剂学杂志, 2013,19(23):317-320. DOI： 10.11653/syfj2013230317.

JIAO Ying-hua, XING Lei, TIAN Fa-ming, et al. Clinical Study of Jieju Fushenning in Treatment of Early Type Ⅱ Diabetic Nephropathy[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(23): 317-320. DOI： 10.11653/syfj2013230317.

摘要

目的: 探讨解聚复肾宁治疗早期糖尿病肾病（DN）的临床疗效。方法: 研究对象为我院收治的120例早期2型DN患者，将其随机分为解聚复肾宁组、厄贝沙坦组、解聚复肾宁+厄贝沙坦组、对照组。每组各30例，12周为1疗程，观察各组治疗前后相关指标的变化。结果: 解聚复肾宁组治疗后空腹血糖、24 h尿微量白蛋白排泄率、血肌酐、糖化血红蛋白等指标显著好转，血清和尿液中血管紧张素Ⅱ（AngⅡ），结缔组织生长因子（CTGF）均显著降低，解聚复肾宁和厄贝沙坦联合治疗明显优于两类药物单独应用（P<0.05）。结论: 解聚复肾宁对早期2型DN疗效确切，可延缓病情进展，提高患者的生活质量，值得临床推广使用。

Abstract

Objective: To investigate the clinical efficacy of Jieju Fushenning(JJFSN) in the treatment of early diabetic nephropathy. Method: One hundred and twenty patients with early type Ⅱ DN admitted to our hospital were randomly divided into JJFSN group

Irbesartan group

JJFSN and Irbesartan group

and control group

each group had 30 patients

with 12 weeks as a treatment course.The changes of relevant indicators before and after treatment were observed. Result: In the JJFSN group

the fasting plasma glucose

urinary albumin excretion rate

serum creatinine

glycosylated hemoglobin A1c and other indicators significantly improved.Blood angiotensinⅡ

blood connective tissue growth factor(CTGF)

urinary angiotensin Ⅱ

urinary CTGF significantly reduced.The combined application of JJFSN with Irbersartan had better clinical effect than that of Irbersartan and JJFSN used respectively(P<0.05). Conclusion: Jieju Fushenning is effective in the treatment of early type Ⅱ DN

can delay disease progression and improve patients quality of life

thereby worthy of clinical application.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

莪术对糖尿病肾病大鼠的保护作用

养阴固精化痰渗湿方联合贝那普利对早期糖尿病肾病大鼠的保护作用

左归降糖益肾方对糖尿病肾病MKR鼠肾组织TGF-及CTGFmRNA表达的影响

HIF-1α在糖尿病肾病中的机制研究及中医药改善作用的研究进展

保肾方治疗气阴两虚、肾络瘀阻证糖尿病肾病Ⅳ期的随机对照试验